ONCODESIGN specializes in preclinical pharmacological evaluation services of new cancer therapies on behalf of the pharmaceutical and biotechnological companies. The group also provides research and development of drugs and biomarkers primarily for the treatment of cancer. The group's activity is organized around 3 business units:
- Service: discovery, identification and selection of new therapeutic targets in oncology;
- Biotech: development of a portfolio of therapeutic and diagnostic projects alone or through partnerships;
- Artificial Intelligence: development of a platform for selecting new therapeutic targets in oncology.
60.3% of sales are abroad.
More about the company